Cellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 (NASDAQ:CLRB)
· seekingalpha.com
Cellectar Biosciences (CLRB) Q1 2026 earnings call: iopofosine 12-month CLOVER data, $140M financing, Phase III & FDA timeline to 2027.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...